Oral Mucositis – New Treatment Options

Oral Mucositis is a common side effect of chemotherapy and or radiation treatment in which painful mouth sores develop. Strategies for treatment of mucositis seek to provide symptomatic relief as well as address the underlying pathobiology. A basic principle of treating oral mucositis is maximizing contact time between therapeutic agents and the oral mucosal tissue. Poor contact time between medication and mucosa could detract from desired outcomes. 

At HDRX, a mucoadhesive polymer technology is utilized to hold medication in contact with the injured oral tissue. Mucoadhesive technology optimizes contact time between medication and oral mucosa.

Insights into the inflammatory and destructive processes underlying mucositis have led to research of new therapeutic agents. Some therapeutic agents that can be delivered via the HDRX mucoadhesive polymer technology are described below. 

Symptomatic Support

Mucoadhesive polymer technology provides hydration support and facilitates extended contact

between membranes and prescribed therapy. 

Supersaturated calcium phosphate mouth rinse treatment has been found to reduce the severity and duration of oral mucositis, resulting in the less frequent use of pain killers among patients treated with BEAM, a high-dose chemotherapy treatment. 

Lidocaine provides relief for mucositis-associated pain.  

Pathobiological Support

Anti-Inflammatory

Pentoxifylline is an anti-inflammatory inhibiting IL-1B, IL6, IL8, and TNF-a and has been shown to reduce the severity of radiotherapy-induced mouth pain in head and neck cancer patients. Anti-Oxidant

Glutamine (GLN) is an amino acid with immunomodulatory properties. GLN has been shown to decrease oxidative stress-related gene expression and increases antioxidant potential. In head and neck cancer patients, GLN has been shown to reduce frequency and duration of grade 3 and grade 4 mucositis.

N-Acetyl-cysteine is a thiol-containing amino acid with anti-oxidant activity and potential radioprotective properties.

Epithelial Growth Factor

Phenytoin is an epithelial growth factor stimulant demonstrating resolution of mucositis lesions in an average of 4.5 days.  

Features of HDRX Compounds for Mucositis

  1. Mucoadhesive delivery- enhanced contact time to deliver curative ingredients to injured mucous membrane.  
  2. Room temperature storage
  3. Sugar-Free, Alcohol-free
  4. Multi-ingredient Synergy

Consult with a Health Dimensions (HDRX) clinical pharmacist today, 800.836.2303. 

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

Subscribe to Get the Latest Rx Insights!

MPA logo - health dimensions clinical pharmacy is michigan pharmacists association member
PCAB Logo - HDRX is an Accredited Compounding Pharmacy
HDRX is an Alliance for Pharmacy Compounding member - logo
PCCA - Health Dimensions Clinical Pharmacy is a PCCA member
Health Dimensions is an APMS member
Pharmacy Compounding Accreditation Board - Logo
podiatry and compounding

How Podiatrists Work with Compounding Pharmacists

Regardless of the medications involved, the close partnership between a podiatrist and a compounding pharmacy provides ...

This is a Text Box

divimegapro-55825

This is a CTA

Test box with CTA

A

This is a blurb

This is text on a blurb

Skip to content